Sampson, Chris http://orcid.org/0000-0001-9470-2369
Zamora, Bernarda
Watson, Sam
Cairns, John
Chalkidou, Kalipso
Cubi-Molla, Patricia
Devlin, Nancy
García-Lorenzo, Borja
Hughes, Dyfrig A.
Leech, Ashley A.
Towse, Adrian
Funding for this research was provided by:
The Association of the British Pharmaceutical Industry
Article History
Accepted: 29 March 2022
First Online: 7 June 2022
Declarations
:
: CS assembled the writing group and led the drafting of the manuscript. All authors contributed to writing and editing all parts of the manuscript.
: This work was funded by an unconditional grant from the Association of the British Pharmaceutical Industry (ABPI). The funder had no role in establishing the writing group, the decision to publish, or the preparation of the manuscript. The ABPI funded open access publication of this article. The views expressed in this article are those of the authors and do not represent the views of the ABPI or its members.
: CS, PCM, and AT are employees of the Office of Health Economics, which receives financial support from the ABPI and provides consultancy services to pharmaceutical companies. BZ, SW, JC, KC, ND, BGL, DAH, and AL declare that they have no conflicts of interest.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.